Abnormal F-18 Fluorodeoxyglucose Uptake of the Lung in Immunocompromised Lymphoma Patients in Complete Remission: Report of Two Cases and Revision of Literature

Abstract

Limited data suggest that F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) may have a role in diagnosing infection. Here we present two cases of lymphoma patients in complete response (CR) who presented during follow-up dry cough and fever. Physical examination and serum evaluations were negative for lymphoma while whole body FDG-PET showed lung uptake which posed a differential diagnosis between relapse of lymphoma and an atypical pneumonia due to persistent lymphopenia. In both cases, cytology examination of sputum suggested Pneumocystis Jiroveci pneumonia (PJP). After appropriate antibiotic treatment, the follow-up examination showed complete resolution of the lung changes revealed by FDG-PET. False-positive results on FDG-PET were supposed to be due to the high uptake of FDG in non-neoplastic inflammatory cellular elements such as macrophages and lymphocytes. Our findings suggest that in cases of FDG-PET positive images in immunocompromised patients with previous hematologic disease, caution must be used, and differential diagnosis might include infections such as PJP in addition to relapse of disease.

Keywords

F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)lymphoma immunocompromised patients Pneumocystis Carinii pneumonia

References

Terasawa

Dahabreh

Nihashi

. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: A systematic review and meta-analysis. Oncologist 2010; 15:750–59.

Cheson

Pfistner

Juweid

. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579–86.

Seam

Juweid

Cheson

. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507–16.

Delbeke

Stroobants

de Kerviler

Gisselbrecht

Meignan

Conti

. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009; 14(S):30–40.

Bakheet

Saleem

Powe

Al-Amro

Larsson

Mahassin

. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000; 25:273–78.

Rodriguez

Fishman

. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770–82.

Thomas

Jr Limper

. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007; 5:298–308.

Ahmed

Jaspan

. Case report: Hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am J Med Sci 1993; 306:313–16.

Kubota

Yamada

Tada

Ido

Tamahashi

. Active and passive mechanisms of (fluorine-18) fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: A microautoradiographic study. J Nucl Med 1994; 35:1067–75.

10.

Shiraki

Hara

Ogino

Shibamoto

Iida

Tamaki

Murase

Eimoto

. False-positive and true-negative hilar and mediastinal lymph nodes on FDG-PET-radiological-pathological correlation. Ann Nucl Med 2004; 18:23–28.

11.

Vahid

Marik

. Infiltrative lung diseases: Complications of novel antineoplastic agents in patients with hematological malignancies. Can Respir J 2008; 15:211–16.

12.

Epier

. Drug-induced bronchiolitis obliterans organizing pneumonia. Clin Chest Med 2004; 25:89–94.

13.

Kolstad

Holte

Fossa

Lauritzsen

Gaustad

Torfoss

. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. Haematologica 2007; 92:139–40.

14.

Kamel

O'Connor

Lee

Filshie

Nandurkar

Tarn

. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:797–801.

15.

Katsuya

Suzumiya

Sasaki

Ishitsuka

Shibata

Takamatsu

Tamura

. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50:1818–23.

16.

Nakazato

Mihara

Sanada

Suzuki

Aisa

Iwabuchi

Kakimoto

. Pneumocystis jiroveci pneumonia detected by FDG-PET. Ann Hematol 2010; 89:839–40.

17.

Sojan

Chew

. Pneumocystis carinii pneumonia on F-18 FDG PET. Clin Nucl Med 2005; 30:763–64.

18.

Huang

Liu

. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol 2011; 90:1145–51.

19.

Liote

. Organizing pneumonia associated with rituximab: Challenges raised by establishing causality. Joint Bone Spine 2008; 75:260–62.

20.

Nieuwenhuizen

Verzijlbergen

Wiltink

Grutters

Biesma

. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma. Haematologica 2008; 93:1267–69.

21.

Ghesquieres

. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005; 16:1399.

22.

Kumar

Basu

Torigian

Anand

Zhuang

Alavi

. Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev 2008; 21:209–24.